直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

At the PTAB Blog

Speak Now or Forever Hold Your Peace - Avoiding Future Estoppel Challenges

June 3, 2021

Authored and Edited by Melissa C Santos, Ph.D.; Kyu Yun Kim; Brooke M Wilner; Thomas Lee Irving; Stacy Lewis*

Holding

In Olaplex, Inc. v. L'Oréal USA, Inc., --F. App’x.__ (Fed. Cir. May 6, 2021) (Taranto, Dyk, and Reyna) (non-precedential), the Court of Appeals for the Federal Circuit (“Federal Circuit”) vacated the infringement judgment and remanded the case.[1] 

Background

The patents at issue initially were U.S. Pat. Nos. 9,498,419 (“the ’419 patent”) and 9,668,954 (“the ’954 patent”). However, after several other proceedings, the only claims remaining at issue were claims 14-16 of the ’954 patent.[2]

In the district court, L’Oréal raised the affirmative defense that claims 14–16 of the ’954 patent were invalid for obviousness and lack of written description support. See Liqwd, Inc. v. L'Oréal USA, Inc., 2019 U.S. Dist. LEXIS 215668 (D. Del. December 16, 2019).

The jury, however, found that L’Oréal did not prove invalidity of the claims 14-16 and awarded damages against L’Oréal for its willful trade secret misappropriation, willful patent infringement, and breach of contract.[3] L’Oréal then renewed its motion for judgement as a matter of law (“JMOL”) and also moved for a new trial. The district court denied such motions.

On appeal, L’Oréal argued that it should have been granted JMOL that claims 14-16 of the ’954 patent are invalid because the written description did not support the entire scope of the claimed ranges. Furthermore, L’Oréal argued that the district court erred in instructing the jury on obviousness in a way inconsistent with KSR International Co. v. Teleflex Inc., 550 U.S. 398 (2007). The jury was instructed that “’[f]or you to find an asserted claim obvious, you must find that there was some teaching, suggestion or incentive to combine the items in the prior art into the particular claimed combination,’ and the ‘suggestion to combine must be clear and particular.’”  L’Oréal Opening Brief, p. 43-44 (emphasis in Brief). According to L’Oréal, “KSR rejected the mandatory ‘Teaching-Suggestion-Motivation’ (TSM) test, … and the relevance of the inventor’s motivation or purpose, for ‘[w]hat matters is the objective reach of the claim[.]’” Id. at 44.

Federal Circuit

The Federal Circuit began by deciding that 35 U.S.C. § 325(e) applies to estop L’Oréal’s challenge to the written description and obviousness verdicts because those arguments could have reasonably been raised by L’Oréal during the post-grant review (“PGR”) of the ‘954 patent. The Federal Circuit held that estoppel applied even though “Olaplex raised it here later than it should have.” Olaplex, --F. App’x.__ at *23. This exercise of discretion was permissible because, “[t]he point in time at which the issue generally must be raised is not apparent on the face of the statute and has not been decided by this court.” Id. at *24. Moreover, “the estoppel issue before us requires no additional factfinding. … [a]nd L’Oréal has not demonstrated any sandbagging by Olaplex or any concrete prejudice from any delay in Olaplex’s raising the issue.” Id. at *25.

Estoppel applied because, in contrast to an inter partes reviews (“IPR”), lack of written description is an authorized ground for challenge in a PGR. “[N]othing prevented L’Oréal from raising the written-description challenge.” Id. at *26.[4]

Although L’Oréal relied on a different prior art combination in the PGR, the Federal Circuit noted that “the possibility of different prior-art references is inherent in the two-forum problem that is the subject of § 325(e), and it would hardly have been obscure to Congress. The Federal Circuit continued:

This possibility, the only basis of L’Oréal’s argument against estoppel on the obviousness challenge, would not justify an exception to the provision without severely weakening the evident function of the provision by generally allowing challengers, having lost on certain prior-art combinations before the Board, to press others in court. L’Oréal, which has not identified any basis for its challenge here that was unavailable at the time of its Board petition, could have reasonably raised in the post-grant review the prior-art combination it raised here.

Id. at *26-27.

In a separate decision, Olaplex, Inc. v. L’Oreal USA, Inc., 845 Fed. Appx. 943 (Fed. Cir. Mar. 4, 2021) (non-precedential), the Federal Circuit vacated the district court’s grant of summary judgment of infringement and permanent injunction. The Federal Circuit held that that decision of March 4 required vacating the infringement and damages verdict in this May 6 case and a remand to the trial court.[5]

Takeaway Lessons

It has always been expected that because the grounds for PGR are broader than those authorized for IPRs, which are limited to 35 U.S.C. §§ 102 and 103, the estoppel impact from a PGR would be broader as well. This case provides an example of that broader impact. Although it is not certain a court will always allow raising the estoppel bar so late in a proceeding, practitioners should be reminded that judicial and administrative proceedings do not occur in silos, but rather occurrences in either may impact the other. For more on the estoppel provisions relating to IPRs and PGRs, see https://www.finnegan.com/en/insights/blogs/at-the-ptab-blog/where-are-we-now-are-you-estopped-or-not.html


[1]The Federal Circuit also reversed the judgment of liability for trade secret misappropriation and breach of contract.

[2]For a previous blog post on the unpatentability of '954 patent claims, see https://www.finnegan.com/en/insights/blogs/at-the-ptab-blog/is-it-hindsight-or-was-it-already-there.html .

[3] The damages awards totaled $49,920,000.

[4]Interestingly, L’Oréal did challenge the claims of the ‘954 patent for lack of written description support, but that petition was denied (PGR2018-00024, Paper 12 (P.T.A.B. Aug. 10, 2018)).

[5]On May 19, 2021, L’Oréal and Olaplex reached a settlement after the Federal Circuit ruling. Although the Federal Circuit ordered a new trial on patent infringement, the two companies stated that they stipulate to the dismissal of the action with prejudice. See https://www.law360.com/ip/articles/1386567/l-oreal-olaplex-settle-after-fed-circ-nixes-66m-ip-verdict?nl_pk=363e6acc-3e7c-461f-ae85-22286bf9c1da&utm_source=newsletter&utm_medium=email&utm_campaign=ip.

Tags

35 U.S.C. § 325(e), estoppel, United States Court of Appeals for the Federal Circuit (CAFC), Patent Trial and Appeal Board (PTAB)

Related Practices

Appeals, Issues, and Legal Strategy

Federal Circuit and Supreme Court Appeals

Patent Office Invalidation Proceedings

PTAB Invalidation Proceedings: IPR and PGR

Related Industries

Consumer Goods and Services

Consumer Products

Related Offices

Washington, DC

*Stacy Lewis is a Law Clerk at Finnegan. 

Copyright © 2021 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 


DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.

Related Insights

Conference

7th International Conference on Biofuels and Bioenergy

June 25-26, 2026

Edinburgh

Conference

IPBC Global 2026

June 15-17, 2026

San Diego

Articles

Colorado Replaces Landmark AI Act: An Overview of the New SB 26-189 Framework

May 26, 2026

At the PTAB Blog

Before the Holding, the Message: Director Squires Uses Magnolia Medical to Outline PTAB Discretionary Denial Policy Changes

May 20, 2026

Conference

Best Practices and Tech in Intellectual Property Conference 2026

May 17, 2026

Tel Aviv

Articles

COPPA’s Amended Rule Is Now in Full Effect: What Operators Need to Know

May 15, 2026

Seminar

IP Strategy at the Crossroads: Technology, Enforcement, and Contracts

May 15, 2026

Taipei

Federal Circuit IP Blog

Federal Circuit Affirms § 102(b) Invalidity; Source Code Commands Are Not Hearsay

May 14, 2026

Conference

2026 AIPLA Spring Meeting

May 13-15, 2026

San Francisco

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP